Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of irofulven-based regimens
compared to mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer
(HRPC) whose disease has progressed following Taxotere based regimens.